The long-term outcome of children with TEL-AML1-positive acute lymphoblastic leukemia (ALL) is uncertain. Although studies of newly diagnosed cases have indicated that the TEL-AML1 fusion confers a favorable prognosis, analyses of relapsed cases have suggested that this may not be true. Because of treatment implications for this subgroup of patients, we have now analyzed 49 cases of relapsed ALL for the presence of TEL-AML1. Only 10% of these cases expressed the fusion, compared to 20-25% of newly diagnosed ALL cases. Additional follow-up of the cohort of 48 newly diagnosed patients with the TEL-AML1 fusion previously reported showed that the 10-year cumulative risk of relapse was 9 ؎ 5% (s.e.). Together, these results suggest an excellent outcome for TEL-AML1-positive ALL.
Introduction
Modern treatment protocols for childhood acute lymphoblastic leukemia (ALL) use clinical features, early response to therapy, and molecular genetic alterations of lymphoblasts to classify patients into three general categories: low-risk, standard-risk, and high-risk. 1 Patients predicted to have a low relapse risk are generally treated with antimetabolite-based therapy, whereas those with an intermediate risk of failure are given intensified, and hence more toxic, therapy. 1 Patients with high-risk ALL are candidates for allogeneic hematopoietic stem cell transplantation in first remission. Molecular abnormalities presently used as risk-stratifying features include the E2A-PBX1, BCR-ABL and MLL-AF4 fusion genes. 1 Recently, we have suggested that the TEL-AML1 fusion, created by the t(12;21)(p13;q22), confers a favorable prognosis and should therefore be added to this list. [2] [3] [4] [5] Other investigators have also reported an excellent outcome for TEL-AML1-positive ALL. 6, 7 However, some studies have demonstrated a high incidence (20-24%) of the TEL-AML1 fusion in relapsed cases of ALL, thereby casting doubt as to the prognostic significance of this genetic alteration. 8, 9 To address this important therapeutic issue, we have now analyzed the incidence of TEL-AML1 in cases of relapsed ALL treated at our institution. preserved at the time of relapse and available for analysis at this time. These cases were treated on St Jude Total Therapy Studies XI 10 (20 cases), XII 11 (16 cases) or XIII 12 (13 cases). Cases were analyzed for the presence of the TEL-AML1 fusion transcript by RT-PCR as previously described. 2 Cumulative incidence functions of leukemic relapse were estimated as described by Prentice et al 13 and compared by Gray's test.
Patients and methods
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Results and discussion
Five of 49 cases of relapsed ALL expressed the TEL-AML1 fusion transcript. The presenting features of these five cases did not differ from previously reported TEL-AML1-positive ALL cases who remain in complete remission: each had B-precursor ALL with a DNA index of 1.0 (Table 1) . These patients were diagnosed at ages 2.1 to 10.9 years (median, 3.8 years) and had initial leukocyte counts of 3.4 to 39 × 10 9 /l (median, 18.5 × 10 9 /l). The time to relapse ranged from 2.6 to 8.3 years (median, 4.1 years). All cases analyzed at diagnosis also expressed TEL-AML1 in their diagnostic specimens.
Because of a tendency for late relapse among TEL-AML1-positive cases, we also performed an updated analysis of relapse among 188 previously described cases, 48 of which demonstrated TEL gene rearrangements. 5 Although one additional hematologic relapse has occurred in a TEL-AML1-positive case since our initial report, the 10-year cumulative incidence of relapse is only 9 ± 5% in this group of patients (Figure 1) , with a median follow-up time of 8.4 years (range, 5.8-3.6 years). In an analysis that considered other types of failure (secondary acute myeloid leukemia, death) as competing causes of failure, the cumulative incidence functions differed significantly (P Ͻ 0.001) between TEL-AML1-positive and TEL-AML1-negative cases (Figure 1) .
The results presented here are consistent with earlier reports indicating a favorable prognosis for ALL patients whose leukemic lymphoblasts express TEL-AML1. [2] [3] [4] [5] [6] [7] We previously demonstrated a 5-year event-free survival estimate of 91 ± 5% for this group of patients, 5 and have now shown that with additional follow-up, the cumulative incidence of relapse remains less than 10%. In addition, only 10% of relapsed ALL cases analyzed in the present study expressed TEL-AML1, compared to an incidence of 20-25% in newly diagnosed cases.
The reason for the apparent discrepancies between our studies and those showing a high frequency of TEL-AML1 at relapse 8, 9 is not clear. Treatment intensity is a powerful prognostic factor that can alter, or even abolish, the clinical significance of genetic alterations. 1 In this regard, a recent analysis of children with ALL treated in Japan demonstrated that TEL-AML1-positive patients treated with an antimetabolitebased nonintensive regimen had a 5-year disease-free survival (DFS) rate of only 55 ± 15%, whereas those treated on a more EPB, early pre-B lineage ALL.
Figure 1
Cumulative incidence of relapse. The 10-year cumulative incidence of relapse is 9 ± 5% for 48 TEL-AML1-positive ALL cases and 34 ± 5% for 140 TEL-AML1-negative cases. recent and intensive protocol had a 5-year DFS rate of 100%. 15 However, relapsed cases described in the aforementioned studies 8, 9 were initially treated on successful BFM protocols, making it unlikely that treatment intensity alone explains the differences. It has also been suggested that relapse among TEL-AML1-positive ALL cases is not decreased, but only delayed. 8 Again, this is not a probable explanation, as we have observed a low relapse rate even after extended follow-up. Finally, selection bias may affect the results of any study that utilizes banked material. Unfortunately, in the present study, cryopreserved bone marrow specimens were available on only 49 of 137 relapsed cases. We therefore cannot rule out the possibility that these 49 cases do not accurately represent the relapsed population as a whole.
In summary, we have demonstrated that children with TEL-AML1-positive ALL do, indeed, have a favorable prognosis when treated with contemporary chemotherapy. Unfortunately, the small percentage of patients who will ultimately relapse cannot be identified by their presenting features, suggesting that all TEL-AML1-positive patients require close longterm monitoring. In this regard, TEL-AML1 has been used as a target to detect minimal residual disease, 16, 17 and may prove to be a useful tool for monitoring this group of patients. All newly diagnosed ALL cases should therefore be screened for this genetic alteration so that these patients can receive appropriate risk-adapted therapy and suitable monitoring. Future studies will focus on defining the optimal therapy for TEL-AML1 leukemia to further improve cure rates and decrease treatment-related morbidity.
(At the time of going to press, we have been informed that a paper by Zuna et al, 18 who also report a low frequency of TEL-AML1 fusion in relapsed ALL, is being published in this issue of Leukemia.)
